The role of serotonergic agents as treatments for alcoholism

Drugs of Today

Volumn 39, Issue 9, 2003, Pages 665-672

  Johnson, Bankole A ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BUSPIRONE; ONDANSETRON; RITANSERIN; SEROTONIN 1 AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ALCOHOLISM; ANIMAL EXPERIMENT; ANXIETY DISORDER; COMORBIDITY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; MACACA; MAJOR CLINICAL STUDY; NONHUMAN; REVIEW;

ALCOHOLISM; HUMANS; SEROTONIN AGENTS;

EID: 0242427463     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.9.799475     Document Type: Review

References (85)

1. Murphy, J.M., Waller, M.B., Gatto, G.J., McBride, W.J., Lumeng, L., Li, T.K. Effects of fluoxetine on the intragastric self-administration of ethanol in the alcohol preferring P line of rats. Alcohol 1988, 5: 283-6.
2. Daoust, M., Chretien, P., Moore, N., Saligaut, C., Lhuintre, J.P., Boismare, F. Isolation andstriatal (3H) serotonin uptake: Role in the voluntary intake of ethanol by rats. Pharmacol Biochem Behav 1985, 22: 205-8.
3. Geller, I. Effects of para-chlorophenylalanine and 5-hydroxytryptophan on alcohol intake in the rat. Pharmacol Biochem Behav 1973, 1: 361-5.
4. Gill, K., Amit, Z., Koe, B.K. Treatment with sertraline, a new serotonin uptake inhibitor, reduces voluntary ethanol consumption in rats. Alcohol 1988, 5: 349-54.
5. Gill, K., Filion, Y., Amit, Z. A further examination of the effects of sertraline on voluntary ethanol consumption. Alcohol 1988, 5: 355-8.
6. Zabik, J.E., Binkerd, K., Roache, J.D. Serotonin and ethanol aversion in the rat. In: C.A. Naranjo and E.M. Sellers (Eds.). Research Advances in New Psychopharmacological Treatments for Alcoholism: Proceedings of the Symposium, Toronto, 4-5 October 1984. Excerpta Medica: Amsterdam 1985.
7. Blundell, J.E. Serotonin and appetite. Neuropharmacology 1984, 23: 1537-51.
8. Blundell, J.E., Latham, C.J. Behavioural pharmacology of feeding. In: T. Silverstone (Ed.). Drugs and Appetite. Academic Press: London 1982.
9. Gill, K., Amit, Z. Serotonin uptake blockers and voluntary alcohol consumption. A review of recent studies. Recent Dev Alcohol 1989, 7: 225-48.
10. Leander, J.D. Fluoxetine suppresses palatability-induced ingestion. Psychopharmacology 1987, 91: 285-7.
11. Stellar, J.R., Stellar, E. The neurobiology of motivation and reward. Springer-Verlag: New York 1985.
12. Barreto Medeiros, J.M., Cabral Filho, J.E., De Souza, S.L. et al. Early malnourished rats are not affected by anorexia induced by a selective serotonin reuptake inhibitor in adult life. Nutr Neurosci 2002, 5: 211-4.
13. Li, E.T., Anderson, G.H. 5-Hydroxytryptamine control of meal to meal composition chosen by rats. Fed Proc 1983, 42: 542-8.
14. Wurtman, J.J., Wurtman, R.J. Fenfluramine and fluoxetine spare protein consumption while suppressing caloric intake by rats. Science 1977, 198: 1178-80.
15. Wurtman, J.J., Wurtman, R.J. Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats. Life Sci 1979, 24: 895-903.
16. Fantino, M. Role of sensory input in the control of food intake. J Auton Nerv Syst 1984, 10: 347-58.
17. Smith, G.P. The physiology of the meal. In: T. Silverstone (Ed.). Drugs and Appetite. Academic Press: London 1982.
18. Wise, R.A., Raptis, L. Effects of pre-feeding on food-approach latency and food consumption speed in food deprived rats. Physiol Behav 1985, 35: 961-3.
19. Naranjo, C.A., Kadlec, K.E., Sanhueza, P., Woodley-Remus, D., Sellers, E.M. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 1990, 47: 490-8.
20. Naranjo, C.A., Poulos, C.X., Bremner, K.E., Lanctot, K.L. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther 1992, 51: 729-39.
21. Naranjo, C.A., Sellers, E.M. Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers. Recent Dev Alcohol 1989, 7: 255-66.
22. Naranjo, C.A., Sellers, E.M., Roach, C.A., Woodley, D.V., Sanchez-Craig, M., Sykora, K. Zimelidine-induced variations in alcohol intake by non-depressed heavy drinkers. Clin Pharmacol Ther 1984, 35: 374-81.
23. Naranjo, C.A., Sellers, E.M., Sullivan, J.T., Woodley, D.V., Kadlec, K., Sykora, K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987, 41: 266-74.
24. Gorelick, D.A., Paredes, A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992, 16: 261-5.
25. Kranzler, H.R., Burleson, J.A., Korner, P. et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995, 152: 391-7.
26. Kranzler, H.R., Burleson, J.A., Brown, J., Babor, T.F. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 1996, 20: 1534-41.
27. Pettinati, H.M., Volpicelli, J.R., Kranzler, H.R., Luck, G., Rukstalis, M.R., Cnaan, A. Sertraline treatment for alcohol dependence: Interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000, 24: 1041-9.
28. Cornelius, J.R., Salloum, I.M., Ehler, J.G. et al. Fluoxetine in depressed alcoholics: A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997, 54: 700-5.
29. Mason, B.J., Kocsis, J.H., Ritvo, E.C., Cutler, R.B. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996, 275: 761-7.
30. McGrath, P.J., Nunes, E.V., Stewart, J.W. et al. Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. Arch Gen Psychiatry 1996, 53: 232-40.
31. Collins, D.M., Myers, R.D. Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol 1987, 4: 49-56.
32. Privette, T.H., Hornsby, R.L., Myers, R.D. Buspirone alters alcohol drinking induced in rats by tetrahydropapaveroline injected into brain monoaminergic pathways. Alcohol 1988, 5: 147-52.
33. Meert, T.F. Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. Alcohol Alcohol 1993, 28: 157-70.
34. Wilson, A.W., Costall, B., Neill, J.C. Manipulation of operant responding for an ethanol-paired conditioned stimulus in the rat by pharmacological alteration of the serotonergic system. J Psychopharmacol 2000, 14: 340-6.
35. Malcolm, R., Anton, R.F., Randall, C.L., Johnston, A., Brady, K., Thevos, A. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992, 16: 1007-13.
36. Kranzler, H.R., Burleson, J.A., Del Boca, F.K. et al. Buspirone treatment of anxious alcoholics: A placebo-controlled trial. Arch Gen Psychiatry 1994, 51: 720-31.
37. Bruno, F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989, 22 (Suppl 1): 49-59.
38. Malec, T.S., Malec, E.A., Dongier, M. Efficacy of buspirone in alcohol dependence: A review. Alcohol Clin Exp Res 1996, 20: 853-8.
39. George, D.T., Rawlings, R., Eckardt, M.J., Phillips, M.J., Shoaf, S.E., Linnoila, M. Buspirone treatment of alcoholism: Age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking. Alcohol Clin Exp Res 1999, 23: 272-8.
40. Meert, T.F., Awouters, F., Niemegeers, C.J., Schellekens, K.H., Janssen, P.A. Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats. Pharmacopsychiatry 1991, 24: 159-63.
41. Myers, R.D., Lankford, M., Bjork, A. Selective reduction by the 5-HT antagonist amperozide of alcohol preference induced in rats by systemic cyanamide. Pharmacol Biochem Behav 1992, 43: 661-7.
42. Svensson, L., Fahlke, C., Hard, E., Engel, J.A. Involvement of the serotonergic system in ethanol intake in the rat. Alcohol 1993, 10: 219-24.
43. Biggs, T.A., Myers, R.D. Naltrexone and amperozide modify chocolate and saccharin drinking in high alcohol-preferring P rats. Pharmacol Biochem Behav 1998, 60: 407-13.
44. Myers, R.D., Lankford, M.F. Suppression of alcohol preference in high alcohol drinking rats: Efficacy of amperozide versus naltrexone. Neuropsychopharmacology 1996, 14: 139-49.
45. Myers, R.D., Lankford, M. Action of the 5-HT2A antagonist amperozide on alcohol-induced poikilothermia in rats. Pharmacol Biochem Behav 1998, 59: 91-5.
46. Lankford, M.F., Bjork, A.K., Myers, R.D. Differential efficacy of serotonergic drugs FG5974, FG5893, and amperozide in reducing alcohol drinking in P rats. Alcohol 1996, 13: 399-404.
47. Overstreet, D.H., McArthur, R.A., Rezvani, A.H., Post, C. Selective inhibition of alcohol intake in diverse alcohol-preferring rat strains by the 5-HT2A antagonists amperozide and FG 5974. Alcohol Clin Exp Res 1997, 21: 1448-54.
48. Ugedo, L., Grenhoff, J., Svensson, T.H. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 1989, 98: 45-50.
49. Awouters, F., Niemegeers, C.J., Megens, A.A., Meert, T.F., Janssen, P.A. The pharmacological profile of ritanserin, a very specific central serotonin-S2 antagonist. Drug Dev Res 1988, 15: 61-73.
50. Johnson, B.A., Jasinski, D.R., Galloway, G.P. et al. Ritanserin in the treatment of alcohol dependence - A multi-center clinical trial. Ritanserin Study Group. Psychopharmacology 1996, 128: 206-15.
51. Wiesbeck, G.A., Weijers, H.G., Chick, J., Naranjo, C.A., Boening, J. Ritanserin in relapse prevention in abstinent alcoholics: Results from a placebo-controlled double-blind international multicenter trial Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 1999, 23: 230-5.
52. Lovinger, D.M., White, G. Ethanol potentiation of 5-hydroxytryptamine-3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons. Mol Pharmacol 1991, 40: 263-70.
53. Zhou, Q., Lovinger, D.M. Pharmacologic characteristics of potentiation of 5-HT3 receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells. J Pharmacol Exp Ther 1996, 278: 732-40.
54. Lovinger, D.M., Zhou, Q. Alcohols potentiate ion current mediated by recombinant 5-HT3RA receptors expressed in a mammalian cell line. Neuropharmacology 1994, 33: 1567-72.
55. Lovinger, D.M. Inhibition of 5-HT3 receptor-mediated ion current by divalent metal cations in NCB-20 neuroblastoma cells. J Neurophysiol 1991, 66: 1329-37.
56. Lovinger, D.M. 5-HT3 receptors and the neural actions of alcohols: An increasingly exciting topic. Neurochem Int 1999, 35: 125-30.
57. Lovinger, D.M. Ethanol potentiates ion current mediated by 5-HT3 receptors on neuroblastoma cells and isolated neurons. Alcohol Alcohol Suppl 1991, 1: 181-5.
58. Hemby, S.E., Johnson, B.A., Dworkin, S.I. Neurobiological basis of drug reinforcement. In: B.A. Johnson and J.D. Roache (Eds.). Drug Addiction and its Treatment: Nexus of Neuroscience and Behavior. Lippincott-Raven: Philadelphia 1997, 137-69.
59. Di Chiara, G., Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988, 85: 5274-8.
60. Koob, G.F. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 1992, 654:171-91.
61. Wise, R.A., Bozarth, M.A. A psychomotor stimulant theory of addiction. Psychol Rev 1987, 94: 469-92.
62. Bloom, F.E., Morales, M. The central 5-HT3 receptor in CNS disorders. Neurochem Res 1998, 23: 653-9.
63. Kilpatrick, G.J., Jones, B.J., Tyers, M.B. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 1987, 330: 746-8.
64. Kilpatrick, G.J., Hagan, R.M., Gale, J.D. 5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system. Behav Brain Res 1996, 73: 11-3.
65. Oxford, A-W., Bell, J.A., Kilpatrick, G.J., Ireland, S.J., Tyers, M.B. Ondansetron and related 5-HT3 antagonists: Recent advances. Prog Med Chem 1992, 29: 239-70.
66. Barnes, N.M., Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38: 1083-152.
67. Johnson, B.A., Cowen, P.J. Alcohol-induced reinforcement: Dopamine and 5-HT3 receptor interactions in animals and humans. Drug Dev Res 1993, 30: 153-69.
68. Bradbury, A.J., Costall, B., Domeney, A.M., Naylor, R.J. Laterality of dopamine function and neuroleptic action in the amygdala in the rat. Neuropharmacology 1985, 24: 1163-70.
69. Eison, A.S., Iversen, S.D., Sandberg, B.E., Watson, S.P., Hanley, M.R., Iversen, L.L. Substance P analog, DiMe-C7: Evidence for stability in rat brain and prolonged central actions. Science 1982, 215: 188-90.
70. Hagan, R.M., Jones, B.J., Jordan, C.C., Tyers, M.B. Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat. Br J Pharmacol 1990, 99: 227-32.
71. Costall, B., Domeney, A.M., Naylor, R.J., Tyers, M.B. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 1987, 92: 881-94.
72. Hodge, C.W., Samson, H.H., Lewis, R.S., Erickson, H.L. Specific decreases in ethanol- but not water-reinforced responding produced by the 5-HT3 antagonist ICS 205-930. Alcohol 1993, 10: 191-6.
73. Fadda, F., Garau, B., Marchei, F., Colombo, G., Gessa, G.L. MDL 72222, a selective 5-HT3 receptor antagonist, suppresses voluntary ethanol consumption in alcohol-preferring rats. Alcohol Alcohol 1991, 26: 107-10.
74. Rodd-Henricks, Z.A., McKinzie, D.L., Li, T.K., Crile, R.S., Murphy, J.M., McBride, W.J. Intracranial self-administration of ethanol into the posterior VTA of Wistar rats is mediated by 5-HT3 receptors. In: Scientific meeting of the Research Society on Alcoholism 1999, Santa Barbara, CA. NIAAA (Ed.). Alcohol Clin Exp Res 1999, 23:49A.
75. McBride, W.J., Li, T.K. Animal models of alcoholism: Neurobiology of high alcohol-drinking behavior in rodents. Crit Rev Neurobiol 1998, 12: 339-69.
76. Tomkins, D.M., Le, A.D., Sellers, E.M. Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology 1995, 117: 479-85.
77. Beardsley, P.M., Lopez, O.T., Gullikson, G., Flynn, D. Serotonin 5-HT3 antagonists fail to affect ethanol self-administration of rats. Alcohol 1994, 11: 389-95.
78. Johnson, B.A., Campling, G.M., Griffiths, P., Cowen, P.J. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: A preliminary study in healthy male volunteers. Psychopharmacology 1993, 112: 142-4.
79. Swift, R.M., Davidson, D., Whelihan, W., Kuznetsov, O. Ondansetron alters human alcohol intoxication. Biol Psychiatry 1996, 40: 514-21.
80. Doty, P., Zacny, J.P., de Wit, H. Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. Behav Pharmacol 1994, 5: 461-9.
81. Sellers, E.M., Toneatto, T., Romach, M.K., Somer, G.R., Sobell, L.C., Sobell, M.B. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994, 18: 879-85.
82. Kranzler, H.R., Pierucci-Lagha, A., Feinn, R., Hernandez-Avila, C. Effects of ondansetron in early- vs. late-onset alcoholics: A prospective, open-label study. 26th Annual Scientific Meeting of the Research Society on Alcoholism, June 2003; abst.
83. Johnson, B.A., Roache, J.D., Javors, M.A., et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000, 284: 963-71.
84. Johnson, B.A. Serotonergic agents and alcoholism treatment: Rebirth of the subtype concept - An hypothesis. Alcohol Clin Exp Res 2000, 24: 1597-601.
85. Enoch, M.-A., Schuckit, M.A., Johnson, B.A., Goldman, D. Genetics of alcoholism using intermediate phenotypes. Alcohol Clin Exp Res 2003, 27: 169-76.